Clinical Improvement, Outcomes, Antiviral Activity, and Costs Associated With Early Treatment With Remdesivir for Patients With Coronavirus Disease 2019 (COVID-19)

Article Immunology

Remdesivir for Severe Coronavirus Disease 2019 (COVID-19) Versus a Cohort Receiving Standard of Care

Susan A. Olender et al.

Summary: In a comparative analysis, remdesivir was found to be associated with significantly higher recovery rates and a 62% reduced mortality rate compared to standard-of-care treatment by day 14 in patients with severe COVID-19.

CLINICAL INFECTIOUS DISEASES (2021)

Add to Collection

Article Medicine, General & Internal

Association Between Early Treatment With Tocilizumab and Mortality Among Critically Ill Patients With COVID-19

Shruti Gupta et al.

Summary: A multicenter cohort study found that early treatment with tocilizumab may reduce mortality among critically ill patients with COVID-19. Further research from randomized clinical trials is needed to confirm these findings.

JAMA INTERNAL MEDICINE (2021)

Add to Collection

Article Biochemistry & Molecular Biology

COVID-19-neutralizing antibodies predict disease severity and survival

Wilfredo F. Garcia-Beltran et al.

Summary: Severe cases of COVID-19 show increased inflammatory markers, lymphopenia, pro-inflammatory cytokines, and high antibody levels. High neutralization potency is a predictor of survival. Patient sera can neutralize different strains, indicating cross-protection from reinfection.

CELL (2021)

Add to Collection

Review Infectious Diseases

Remdesivir in Coronavirus Disease 2019 (COVID-19) treatment: a review of evidence

Hui Xian Jaime Lin et al.

Summary: Remdesivir has shown potential as a therapeutic agent against COVID-19, with evidence demonstrating its ability to shorten time to recovery and hospital stay for patients. However, further large-scale clinical trials are needed to validate these findings.

INFECTION (2021)

Add to Collection

Editorial Material Infectious Diseases

The place for remdesivir in COVID-19 treatment

Barnaby Young et al.

LANCET INFECTIOUS DISEASES (2021)

Add to Collection

Article Medicine, General & Internal

Repurposed Antiviral Drugs for Covid-19-Interim WHO Solidarity Trial Results

Summary: The authors of the study reported the interim results of using four repurposed antiviral drugs (remdesivir, hydroxychloroquine, lopinavir, and interferon beta-1a) in hospitalized COVID-19 patients. The study showed that these drug regimens had little or no effect on overall mortality, initiation of ventilation, and duration of hospital stay.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Immunology

SARS-CoV-2 Seroconversion and Viral Clearance in Patients Hospitalized With COVID-19: Viral Load Predicts Antibody Response

Mar Masia et al.

Summary: The study found that viral replication determines the magnitude of antibody response to SARS-CoV-2 in COVID-19 patients, which contributes to viral clearance. Some patients are unable to produce antibodies, exhibiting different virological and clinical profiles.

OPEN FORUM INFECTIOUS DISEASES (2021)

Add to Collection

Review Medicine, General & Internal

Mortality Benefit of Remdesivir in COVID-19: A Systematic Review and Meta-Analysis

Vikas Bansal et al.

Summary: The study suggests that Remdesivir may have benefits in reducing mortality and shortening recovery time for COVID-19 patients, although adverse effects are associated with its use.

FRONTIERS IN MEDICINE (2021)

Add to Collection

Editorial Material Public, Environmental & Occupational Health

Biases in Evaluating the Safety and Effectiveness of Drugs for the Treatment of COVID-19: Designing Real-World Evidence Studies

Christel Renoux et al.

Summary: The COVID-19 pandemic has sparked a surge in observational studies assessing the safety and effectiveness of various treatments, including hydroxychloroquine and renin-angiotensin-aldosterone system inhibitors. Many of these studies have been found to have issues with immortal time bias and selection bias, highlighting the importance of addressing these biases in future research.

AMERICAN JOURNAL OF EPIDEMIOLOGY (2021)

Add to Collection

Review Medicine, General & Internal

Major Update: Remdesivir for Adults With COVID-19: A Living Systematic Review and Meta-analysis for the American College of Physicians Practice Points

Anjum S. Kaka et al.

Summary: The study suggests that remdesivir may not significantly reduce mortality in COVID-19 patients, but it likely improves the percentage of patients who recover and reduces serious harms. It may also result in a small decrease in the proportion of patients needing ventilation.

ANNALS OF INTERNAL MEDICINE (2021)

Add to Collection

Article Infectious Diseases

A real-life setting evaluation of the effect of remdesivir on viral load in COVID-19 patients admitted to a large tertiary centre in Israel

Elad Goldberg et al.

Summary: The study examined the effectiveness of remdesivir in COVID-19 patients and found that it did not significantly affect viral load or reduce hospitalization length. The small size of the remdesivir group may have contributed to the lack of statistically significant differences.

CLINICAL MICROBIOLOGY AND INFECTION (2021)

Add to Collection

Review Medicine, Research & Experimental

Remdesivir for the treatment of COVID-19: A systematic review and meta-analysis of randomized controlled trials

Ahmad Al-Abdouh et al.

Summary: Remdesivir in COVID-19 patients is associated with increased rates of recovery and hospital discharge, along with decreased rates of serious adverse events. However, it does not significantly reduce the time to clinical improvement or mortality.

CONTEMPORARY CLINICAL TRIALS (2021)

Add to Collection

Review Pharmacology & Pharmacy

Remdesivir for treatment of COVID-19; an updated systematic review and meta-analysis

Afra Rezagholizadeh et al.

Summary: The meta-analysis revealed that remdesivir administration in COVID-19 patients was associated with improved 28-day recovery, reduced duration of low flow oxygen support, and decreased risk of invasive mechanical ventilation or extracorporeal membrane oxygenation requirement. Additionally, the remdesivir group had a lower risk of serious adverse drug reactions compared to the control group.

EUROPEAN JOURNAL OF PHARMACOLOGY (2021)

Add to Collection

Article Medicine, General & Internal

Comparison of Time to Clinical Improvement With vs Without Remdesivir Treatment in Hospitalized Patients With COVID-19

Brian T. Garibaldi et al.

Summary: This comparative effectiveness research study showed that the receipt of remdesivir was associated with faster clinical improvement in a cohort of predominantly non-White patients with COVID-19. Additionally, the combination of remdesivir and corticosteroids did not reduce the time to death compared with remdesivir administered alone.

JAMA NETWORK OPEN (2021)

Add to Collection

Review Medicine, General & Internal

Remdesivir therapy in patients with COVID-19: A systematic review and meta-analysis of randomized controlled trials

Charan Thej Reddy Vegivinti et al.

Summary: The study found that treatment with remdesivir reduces the likelihood of COVID-19 patients needing mechanical ventilation or extracorporeal membrane oxygenation and increases the chances of early and late discharge, but has no impact on mortality rates.

ANNALS OF MEDICINE AND SURGERY (2021)

Add to Collection

Article Medicine, General & Internal

Clinical outcomes of different therapeutic options for COVID-19 in two Chinese case cohorts: A propensity-score analysis

Carlos K. H. Wong et al.

Summary: The study found that interferon-beta-1b administered alone or in combination with oral ribavirin showed improved outcomes for COVID-19 patients, while other therapeutic options did not consistently demonstrate clinical benefits.

ECLINICALMEDICINE (2021)

Add to Collection

Article Critical Care Medicine

Early corticosteroids are associated with lower mortality in critically ill patients with COVID-19: a cohort study

Pablo Monedero et al.

Summary: Early use of corticosteroids in critically ill patients with COVID-19 is associated with lower mortality and fewer complications than delayed use.

CRITICAL CARE (2021)

Add to Collection

Review Public, Environmental & Occupational Health

Remdesivir and its antiviral activity against COVID-19: A systematic review

Andri Frediansyah et al.

Summary: Remdesivir exhibits potent antiviral activities against SARS-CoV-2 and has shown efficacy in treating COVID-19 patients in clinical practice, but further efficacy assessments in clinical trials are needed.

CLINICAL EPIDEMIOLOGY AND GLOBAL HEALTH (2021)

Add to Collection

Editorial Material Medicine, General & Internal